| abstract |
The present disclosure relates generally to methods, compositions and dosing regimens for treating, preventing and / or delaying or alleviating the onset or progression of symptoms associated with elevated IFN-γ levels. The present disclosure generally relates to, for example, hemophagocytic lymphohistiocytosis (HLH), hemorrhagic fever, CAR-T cell therapy, transplant failure, graft rejection, graft versus host disease (GvHD), and / or graft rejection To treat, prevent and / or delay or alleviate symptoms associated with elevated levels of interferon gamma (IFNγ, IFN-gamma), such as inflammatory disorders associated with And methods and compositions. |